Shares of POET Technologies rocketed as much as 28.7% to $18.49 on May 14 after announcing a supply and joint development agreement with Lumilens Inc., a venture-backed startup building optical connections for AI data centers. Lumilens placed an initial purchase order worth $50 million for optical engines , representing the first phase of a broader relationship that could scale to $500+ million in cumulative purchases over five years. For a company that reported just $1.1 million in trailing twelve-month revenue, the numbers are staggering — and so are the risks.

  • A Blockbuster Order for a Company That Barely Has Revenue

POET's stock has surged roughly 220% over the past year, pushing its market capitalization to approximately $2.2 billion — yet the company remains unprofitable with revenue of just $1.1 million in the last twelve months.

That produces a price-to-sales ratio above 1,300x , meaning the market is pricing in explosive future growth that hasn't materialized yet. The Lumilens deal gives investors their first concrete dollar figure to model against, but fulfillment depends on successful development, qualification of the modules, and scaling of manufacturing capability — none of which is guaranteed.

  • Replacing Marvell: The Comeback Story Investors Want to Believe

On April 27, POET disclosed that Marvell Semiconductor had canceled all purchase orders associated with Celestial AI , triggering a 47.35% single-day drop.

The speed with which POET announced a new agreement of this scale was a clear signal the market welcomed.

Lumilens is backed by Mayfield, Spark Capital, and other leading venture capital investors , lending the deal some credibility — but it remains a startup-to-startup partnership, not a hyperscaler commitment.

  • Warrants Sweeten the Deal for Lumilens — and Dilute Existing Shareholders

POET granted Lumilens a warrant to purchase up to 22.9 million common shares at $8.25 per share — roughly half today's trading price. The remaining shares vest in tranches tied to cumulative payments toward future purchase orders totaling up to $500 million. If the partnership succeeds, that dilution is the cost of a transformative deal. If it stalls, shareholders absorbed the risk for nothing.

  • The Real Test Is 2027 — Not Today's Price

Engineering samples are expected in late 2026, with production ramp aligned to hyperscaler customer deployments in 2027.

POET is currently fulfilling a $5 million order for optical engines, targeting over 30,000 units this year — a fraction of what the Lumilens deal envisions. Until manufacturing scales from its Malaysian facility, the $50 million order remains a commitment on paper, not cash in the bank.